TG Therapeutics | TGTX - Les Charges D'Exploitation





Les Charges D'Exploitation Changement Date
AbbVie USD 10.27B 538M 2026-03
Alaunos Therapeutics USD 1.19M 148K 2025-09
Amgen USD 4.78B 1.12B 2026-03
Ardelyx USD 120.12M 14.46M 2025-12
Arrowhead Research USD 215M 8.23M 2026-03
Bayer EUR 9.88B 452M 2026-03
Biogen USD 1.96B 69.6M 2026-03
Corcept Therapeutics USD 214.5M 16.87M 2026-03
Curis USD 9.02M 23.01M 2025-12
Gilead Sciences USD 23.52B 18.55B 2026-03
Infinity Pharmaceuticals USD 10.7M 1.54M 2023-06
J&J USD 17.44B 1.53B 2026-03
Karyopharm Therapeutics USD 51.92M 9.9M 2025-12
Novartis USD 9.29B 507M 2026-03
Novavax USD 126.2M 23.62M 2025-12
PTC Therapeutics USD 226.66M 19.64M 2026-03
Puma Biotechnology USD 49.26M 3.2M 2024-06
Regeneron Pharmaceuticals USD 31.42B 28.44B 2026-03
Roche Holding CHF 21.01B 10.84B 2025-12
TG Therapeutics USD 170.12M 28.04M 2026-03
Verastem USD 59.01M 21.98M 2025-12
Vertex Pharmaceuticals USD 1.85B 78.6M 2026-03